Perceptive Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Perceptive Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-26,667	Closed	-$1.26M	–	130
2018 Q1	$1.26M	Hold	26,667	–	–	0.04%	103
2017 Q4	$1.57M	Hold	26,667	–	–	0.05%	93
2017 Q3	$1.65M	Hold	26,667	–	–	0.06%	96
2017 Q2	$1.66M	Buy	+26,667	New	+$1.64M	0.08%	86
2017 Q1	–	Sell	-26,667	Closed	-$1.02M	–	166
2016 Q4	$1.02M	Buy	+26,667	New	+$924K	0.07%	95
2016 Q3	–	Sell	-26,667	Closed	-$964K	–	196
2016 Q2	$964K	Hold	26,667	–	–	0.07%	98
2016 Q1	$1.07M	Buy	+26,667	New	+$980K	0.09%	100
2015 Q4	–	Sell	-26,667	Closed	-$916K	–	157
2015 Q3	$916K	Hold	26,667	–	–	0.07%	97
2015 Q2	$1.44M	Hold	26,667	–	–	0.09%	109
2015 Q1	$1.78M	Buy	+26,667	New	+$1.69M	0.14%	85

Other funds holding BCLI

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CPP

Crow Point Partners Boston, Massachusetts $64M AUM 33.5% 1-Year Est. Return

Perceptive Advisors's BCLI Position: Q2 2018 in Review

Perceptive Advisors sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2018, closing a stake of 26,667 shares — an estimated $1.26M sold.

Perceptive Advisors first reported a position in BCLI in Q1 2015 and held it in 10 quarters. The position peaked at $1.78M in Q1 2015. 39 funds tracked by Wall St. Rank hold BCLI as of Q2 2018.

Perceptive Advisors reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2018 after selling out during the quarter.
Perceptive Advisors sold 26,667 BRAINSTORM CELL THERAPUTC shares in Q2 2018, an estimated $1.26M.
Perceptive Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2015 and held it in 10 quarters.
Perceptive Advisors's BRAINSTORM CELL THERAPUTC position peaked at $1.78M in Q1 2015.
39 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2018.

Based on Perceptive Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.